The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Telix Pharmaceuticals (Innovations) Pty Limited
Exelixis
Barinthus Biotherapeutics
Incyte Corporation
Amgen
Blue Earth Therapeutics Ltd
Laekna Limited
Clarity Pharmaceuticals Ltd
3B Pharmaceuticals GmbH
Lava Therapeutics
Telix Pharmaceuticals (Innovations) Pty Limited
Saving Patients' Lives Medical B.V.
Coherus Oncology, Inc.
Opna Bio LLC
Elevation Oncology
EDAP TMS S.A.
Valerio Therapeutics
Taiho Oncology, Inc.
Seagen Inc.
ESSA Pharmaceuticals
ESSA Pharmaceuticals
Poseida Therapeutics, Inc.
Oncternal Therapeutics, Inc
DisperSol Technologies, LLC
Tango Therapeutics, Inc.
Astex Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Pfizer
Effector Therapeutics
Hookipa Biotech GmbH
AvenCell Therapeutics, Inc.
GTx
Haihe Biopharma Co., Ltd.
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Leap Therapeutics, Inc.
Qure Healthcare, LLC
Pfizer
pharmaand GmbH
Angle plc
Tceleron Therapeutics, Inc.
Novo Nordisk A/S
MagForce USA
Genmab
Nuvation Bio Inc.
AvenCell Therapeutics, Inc.
GTx
InSightec
LTN PHARMACEUTICALS, INC.
Karyopharm Therapeutics Inc
Ferring Pharmaceuticals